[go: up one dir, main page]

FI971568A0 - Menetelmä resistenttien kasvainten hoitamiseksi - Google Patents

Menetelmä resistenttien kasvainten hoitamiseksi

Info

Publication number
FI971568A0
FI971568A0 FI971568A FI971568A FI971568A0 FI 971568 A0 FI971568 A0 FI 971568A0 FI 971568 A FI971568 A FI 971568A FI 971568 A FI971568 A FI 971568A FI 971568 A0 FI971568 A0 FI 971568A0
Authority
FI
Finland
Prior art keywords
procedure
treatment
resistant tumors
tumors
resistant
Prior art date
Application number
FI971568A
Other languages
English (en)
Swedish (sv)
Other versions
FI971568A7 (fi
FI971568L (fi
Inventor
Srinivasan Chandrasekhar
Anne Hollins Dantzig
Robert Lee Shepard
Ii James Jacob Starling
Mark Alan Winter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI971568A0 publication Critical patent/FI971568A0/fi
Publication of FI971568A7 publication Critical patent/FI971568A7/fi
Publication of FI971568L publication Critical patent/FI971568L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI971568A 1994-10-14 1995-10-13 Menetelmä resistenttien kasvainten hoitamiseksi FI971568L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32317694A 1994-10-14 1994-10-14
PCT/US1995/013036 WO1996011677A1 (en) 1994-10-14 1995-10-13 Methods for treating resistant tumors

Publications (3)

Publication Number Publication Date
FI971568A0 true FI971568A0 (fi) 1997-04-14
FI971568A7 FI971568A7 (fi) 1997-06-12
FI971568L FI971568L (fi) 1997-06-12

Family

ID=23258042

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971568A FI971568L (fi) 1994-10-14 1995-10-13 Menetelmä resistenttien kasvainten hoitamiseksi

Country Status (14)

Country Link
US (2) US6121292A (fi)
EP (2) EP0820769A3 (fi)
JP (1) JPH10512544A (fi)
CN (1) CN1168631A (fi)
AU (1) AU702301B2 (fi)
CA (1) CA2202661A1 (fi)
CZ (1) CZ113797A3 (fi)
FI (1) FI971568L (fi)
HU (1) HUT77604A (fi)
IL (1) IL115582A0 (fi)
MX (1) MX9702700A (fi)
NO (1) NO971704L (fi)
WO (1) WO1996011677A1 (fi)
ZA (1) ZA958688B (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
CA2170480A1 (en) * 1995-02-28 1996-08-29 Robin Sharon Lee Fuchs-Young Methods of inhibiting estrogen positive tumors of the brain or cns
CA2236543A1 (en) * 1995-11-07 1997-05-15 Alan David Palkowitz Methods for treating resistant tumors
CA2206752A1 (en) 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
CA2214922A1 (en) * 1996-09-27 1998-03-27 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US6471943B1 (en) 1996-12-30 2002-10-29 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
JP2002513415A (ja) 1997-04-30 2002-05-08 イーライ・リリー・アンド・カンパニー 抗血栓剤
WO1998049160A1 (en) 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
US6288105B1 (en) 1997-04-30 2001-09-11 Eli Lilly And Company Antithrombotic agents
JP2002501503A (ja) 1997-04-30 2002-01-15 イーライ・リリー・アンド・カンパニー 抗血栓症剤
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
CA2346029A1 (en) * 1998-10-02 2000-04-13 Anthony R. Imondi Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
EP0997460B1 (en) * 1998-10-28 2002-12-11 Eli Lilly And Company Benzothiophene compounds as antithrombotic agents and intermediates
WO2000048541A1 (en) * 1999-02-19 2000-08-24 Brooks Norman A Zinc chloride in treating skin diseases
AU2001282410A1 (en) * 2000-08-24 2002-03-22 Dublin City University N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
WO2004010937A2 (en) * 2002-07-26 2004-02-05 Advanced Research & Technology Institute At Indiana University Method of treating cancer
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) * 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2578636A1 (en) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
FR2913017A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
IL311006A (en) * 2014-12-18 2024-04-01 Hoffmann La Roche Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
CN108129375B (zh) * 2018-01-30 2020-04-28 中山大学 化合物及其制备方法与在制备肿瘤耐药逆转剂中的应用
CN117603219B (zh) * 2023-11-29 2025-08-08 浙江大学 一种p-糖蛋白抑制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
HUT71237A (en) * 1993-10-15 1995-11-28 Lilly Co Eli Pharmaceutical compositions for treating resistant neoplasms containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation
JPH09506898A (ja) * 1993-12-21 1997-07-08 イーライ・リリー・アンド・カンパニー 非ペプチドタキキニン受容体アンタゴニスト
AU1440395A (en) * 1993-12-21 1995-07-10 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy

Also Published As

Publication number Publication date
MX9702700A (es) 1997-06-28
JPH10512544A (ja) 1998-12-02
AU3829895A (en) 1996-05-06
IL115582A0 (en) 1996-01-19
NO971704L (no) 1997-05-13
EP0709090A3 (en) 1996-08-28
US6124311A (en) 2000-09-26
CZ113797A3 (en) 1997-09-17
AU702301B2 (en) 1999-02-18
FI971568A7 (fi) 1997-06-12
WO1996011677A1 (en) 1996-04-25
HUT77604A (hu) 1998-06-29
EP0820769A3 (en) 1998-08-19
US6121292A (en) 2000-09-19
NO971704D0 (no) 1997-04-14
ZA958688B (en) 1997-04-14
FI971568L (fi) 1997-06-12
CA2202661A1 (en) 1996-04-25
CN1168631A (zh) 1997-12-24
EP0820769A2 (en) 1998-01-28
EP0709090A2 (en) 1996-05-01

Similar Documents

Publication Publication Date Title
FI971568A0 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
FI970918A0 (fi) Yhdisteet ja menetelmät syövän hoitamiseksi
NO991381L (no) Kombinasjonsterapi for behandling av psykoser
NO991955L (no) FremgangsmÕte for behandling av hydrokarboner
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
DE69507757D1 (de) Unterteilte Substratbehandlungskammer
NO974554L (no) FremgangsmÕte for behandling av en underjordisk formasjon
BR9603841A (pt) Aparelho para o tratamento hipertérmico de tumores
FI963571A0 (fi) Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi
FI962370A0 (fi) Laite tissuen valmistamiseksi
NO990225D0 (no) Medikamenter for behandling av hyperfosfatemi
FI972484L (fi) Karsinooman hoito
FI960658L (fi) Uudet bis-naftalimidit syövän hoitamiseksi
FI973173A0 (fi) Menetelmä kondensaatin käsittelemiseksi
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
NO981822L (no) Anvendelse av proteinet GAX for behandling av cancer
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
NO920983D0 (no) Fremgangsmaate for behandling av nevrodegenerative tilstander
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
FI970717A0 (fi) Menetelmät kohtusyövän inhiboimiseksi
FI970484A0 (fi) Menetelmä heran käsittelemiseksi
FI951441A0 (fi) Menetelmä 5-formyyliamino-pyrimidiinien valmistamiseksi
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse